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Abstract 
 
Background: Although it is well established that methylphenidate (MPH) enhances 
sustained attention, the neural mechanisms underpinning this improvement remain 
unclear. We examined how MPH influenced known electrophysiological (EEG) 
precursors of lapsing attention over different time-scales. 
Methods: We measured the impact of MPH, compared with placebo, on behavioural 
and electrocortical markers while healthy adults (n=40) performed a continuous 
monitoring paradigm designed to elicit attentional lapses.   
Results: MPH led to increased rates of target detection and electrophysiological 
analyses were conducted to identify the mechanisms underlying these 
improvements. Lapses of attention were reliably preceded by progressive increases 
in α-activity that emerged over periods of several seconds. MPH led to an overall 
suppression of α-activity across the entire task but also diminished the frequency of 
these maladaptive pre-target increases through a reduction of α-variability.  A drug-
related linear increase in the amplitude of the frontal P3 event-related component 
was also observed in the pre-target timeframe (3 – 4 s). Further, during immediate 
target processing there was a significant increase in the parietal P3 amplitude with 
MPH, indicative of enhanced perceptual evidence accumulation underpinning target 
detection.  MPH-related enhancements occurred without significant changes to early 
visual processing (visual P1 and 25Hz steady-state visual evoked potential). 
Conclusions: MPH serves to reduce maladaptive electrophysiological precursors of 
lapsing attention by acting selectively on top-down endogenous mechanisms that 
support sustained attention and target detection with no significant effect on 
bottom-up sensory excitability. These findings offer candidate markers to monitor 
the therapeutic efficacy of psychostimulants or to predict therapeutic responses.  
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Trial Registration: 
The study was registered with the Australian and New Zealand Clinical Trials Registry 
(ACTRN)  
(Trial ID: ACTRN12609000625279,  
Url: http://www.anzctr.org.au/ACTRN12609000625279.aspx). 
Scientific title: The effect of methylphenidate, atomoxetine and citalopram versus 
placebo on behavioural and physiological indices of executive control in healthy 
individuals. 
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Introduction 1 
 2 
Although methylphenidate (MPH) is the most universally prescribed psychostimulant for 3 
the treatment of attention deficit hyperactivity disorder (ADHD) (1), we lack a clear 4 
understanding of the neurophysiological bases of its ability to enhance attention.  Such 5 
insights are critical for the identification of robust biomarkers of drug response which 6 
may ultimately facilitate personalised approaches to treatment in disorders such as 7 
ADHD. 8 
 9 
It is well established that MPH leads to reductions in behavioural symptoms of 10 
inattention, in particular, the capacity to sustain attention via modulations of 11 
catecholamine transmission (2). Although functional imaging studies have demonstrated 12 
that MPH strengthens the connectivity of fronto-striato-thalamic networks that are 13 
integral to sustained attention (3, 4) it is less clear how the temporal dynamics of 14 
electro-cortical activity, associated with attentional control in humans, are augmented 15 
by MPH. Some electrophysiological studies have reported correlations of EEG power 16 
(averaged at rest or across task-active conditions) with MPH-related improvements in 17 
sustained attention (5-8). However, it is not apparent if these changes arise from direct 18 
augmentation of sustained attention mechanisms or indirectly through facilitation of 19 
task-relevant cortical regions. For example, behavioural improvements on sustained 20 
attention tasks could potentially be achieved through pharmacological regulation of 21 
sensory encoding, selective attention or working memory capacity. 22 
 23 
The high temporal resolution of EEG offers the potential to pinpoint MPH’s influence on 24 
the electrophysiology of sustained attention as it unfolds in time. O’Connell and 25 
colleagues (9) devised a continuous monitoring paradigm (the continuous temporal 26 
expectancy task, CTET) to facilitate the identification of maladaptive patterns of EEG 27 
activity that predict forthcoming lapses of attention.  Neural activity in the α-frequency 28 
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(8-14 Hz) was predictive of lapses and was observable up to 20s in advance. 29 
Interestingly, the quality of basic sensory encoding, indexed by the steady-state visual 30 
evoked potential (SSVEP) was not predictive of attentional performance suggesting that 31 
lapses arose primarily from a failure to sustain goal-directed attention as opposed to 32 
fluctuations in visual baseline activity. Finally, the parietal P3 was reduced in amplitude 33 
during lapses of attention, indicative of momentary disruption of decision-formation 34 
processes.  35 
 36 
The CTET is thus well suited to identify the neural mechanisms through which 37 
monoaminergic manipulations impact sustained attention. Here, MPH was administered 38 
within a placebo-controlled, double-blinded, cross-over design while participants 39 
undertook the CTET EEG paradigm. We first examined the efficacy of MPH to influence 40 
neural signals at different timescales: 1) across the entire task; 2) in the pre-target 41 
interval; and 3) in the immediate period of target processing. Next, we established 42 
whether MPH impacted all stages of stimulus processing through general effects of 43 
increased arousal and bottom-up visual excitability or, alternatively, whether it acted 44 
more selectively on higher-order endogenous mechanisms that support sustained 45 
attention.  46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
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Materials and methods 57 
 58 
Participants 59 
 60 
Forty individuals (mean age=24.3 years, SD=5.6) participated in the study. All 61 
participants provided informed consent, in accordance with the ethics committee of The 62 
University of Queensland. Inclusion criteria were male, aged 18-45, right-handed, non-63 
smoking, no history of drug abuse, no current use of recreational drugs, no history of 64 
neuropsychiatric disorder and not currently taking psychoactive medication. A 65 
consultant psychiatrist screened all participants using the M.I.N.I. Screen to confirm 66 
absence of psychiatric illness (10). Participants were excluded due to contraindications 67 
to the medication employed in the study (n=4) or a technical fault on day of testing 68 
affecting one condition (n=3). Exclusions from the EEG analyses were due to excessive 69 
EEG channel artifacts (n=4) or because participants had < 10 target hits/misses per 70 
condition (n=3). We note the sample size for each analysis conducted in the results.  71 
Further details regarding participant recruitment, screening, and testing can be found in 72 
Barnes et al (2014) (11).   73 
 74 
Study design and drug administration 75 
 76 
A randomised, double-blinded, placebo-controlled, four-arm cross-over design was 77 
employed (11). Each participant attended four sessions at the same time of day, spaced 78 
at least one week apart. At each session, a single blue gelatine capsule containing 79 
methylphenidate (MPH, 30 mg, mixed dopaminergic and noradrenergic action), 80 
atomoxetine (ATM, 60 mg, primarily noradrenergic action), citalopram (CIT, 30 mg, 81 
primarily serotonergic action) or placebo (PLA, dextrose) was administered. Cognitive 82 
testing began 90 minutes following drug administration, coinciding with the peak 83 
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plasma levels for each of the study drugs (12-14) and doses were selected based upon 84 
clinical relevance (15-17) and demonstrated cognitive effects (18-20). 85 
 86 
Continuous temporal expectancy task (CTET) 87 
 88 
Full details of the task are provided in Supplementary Materials and in O’Connell et al 89 
(2009) (see also Figure 1). Briefly, the CTET(9) involves the central presentation of a 90 
patterned stimulus that changes orientation at regular intervals. Participants monitored 91 
the orientation transitions and made a speeded button-press when they detected 92 
infrequent targets defined by their duration being longer (1120 ms) than the standard 93 
transitions (800 ms). The discrimination of target from non-target frames thus required 94 
continuous monitoring, placing significant demands on sustained attention and 95 
engendering frequent attentional lapses.  To avoid eye movements, participants were 96 
instructed to fixate on a centrally presented white cross throughout the task. The 97 
stimulus also flickered at a rate of 25 Hz in order to generate a steady-state visually 98 
evoked potential (SSVEP) that served as a measure of basic visual stimulus processing.  99 
 100 
Behavioural analysis 101 
 102 
Performance was assessed by determining the proportion of targets that were correctly 103 
identified. Reaction time was measured relative to the point at which target frames 104 
became distinguishable from non-target frames (800 ms post stimulus onset). Button 105 
presses were only considered to represent target detections if they occurred within 2 106 
non-target frames following the target frame (1600ms). The proportion of targets 107 
detected was analysed across all four conditions (MPH, ATM, CIT, PLA). As reported in 108 
the results, only MPH improved sustained attention. Therefore, all subsequent analyses 109 
focused on the direct comparison between the MPH and PLA conditions to isolate 110 
behavioural and electrocortical changes associated with MPH.   In subsequent analyses, 111 
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mean detection latency was calculated, and the coefficient of variation (standard 112 
deviation/mean detection latency) was derived as a measure of response variability for 113 
target detection. Each measure was analysed using repeated measures statistics with 114 
Bonferroni correction. Subjective ratings of alertness were measured using a visual 115 
analogue scale (21); see supplementary material.  116 
 117 
 118 
EEG recording 119 
 120 
EEG was recorded using an ActiveTwo BioSemi system of 64 scalp electrodes with an 121 
equiradial montage (https://www.biosemi.com/headcap.htm), sampled at 1024 Hz. 122 
Vertical eye movements were recorded with two vertical electrooculogram (EOG) 123 
electrodes placed above and below the left eye, while horizontal eye movements were 124 
recorded with two horizontal EOG electrodes placed at the outer canthus of each eye. 125 
 126 
Electrophysiological Analysis 127 
 128 
Data were pre-processed using MATLAB (The Mathworks, Inc.) and the EEGlab plug-in 129 
(22). Pre-processing involved resampling the data to 512 Hz, applying a 40 Hz low-pass 130 
filter and re-referencing data offline to the average of all scalp electrodes.  All electrode 131 
channels were subjected to an artifact criterion of 100 mV to reject trials with excessive 132 
EOG or other noise transients. To remove errors that may have arisen from blinking 133 
rather than true failures of attention, a 4 s interval prior to each target trial was 134 
scanned, and any trial that included an artifact (100 mV) that was evident across eight or 135 
more channels was excluded from all analyses. 136 
 137 
 138 
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Long-term analysis of the EEG amplitude spectrum: A fast-Fourier transform (FFT) was 139 
carried out for all standard frames across all 10 blocks of the CTET. Amplitude spectra, 140 
comprising the time period -80 to 800 ms relative to standard frame onset, were 141 
extracted. Grand average spectra were obtained for activity in the α-band (8-14 Hz) and 142 
the SSVEP (25 Hz) for each Drug condition (MPH, PLA). α-amplitude was measured from 143 
a cluster of parietal and occipital electrodes (CPz, Pz, POz) and SSVEP amplitude was 144 
measured from a midline occipital electrode (Oz) guided by field pattern distribution on 145 
the scalp topographies, centred where amplitude was maximal. Paired t-tests were 146 
conducted to examine differences in α-band and SSVEP amplitude and α-amplitude 147 
variability (stdev/mean) as a function of drug condition.  148 
 149 
Short-term analysis of the pre-target interval: ERP and oscillatory measures of EEG 150 
activity were examined in a time period of 4 seconds that encompassed four standard 151 
frames and the subsequent target frame. This time period was chosen to allow 152 
investigation of pre-target activity without including activity related to previous target 153 
frames, as the minimum interval between targets was 5.6 seconds. An FFT was applied 154 
to derive α-band (8-14 Hz) and SSVEP (25 Hz) amplitude spectra across the epoch -3200 155 
to 800 ms relative to target frame onset. Amplitude measurements were taken from the 156 
same scalp sites as described above for the analysis of the whole task period.  157 
 158 
ERP components of interest were guided by O’Connell et al (2009) (9). Time intervals for 159 
the measurement of ERPs and the definition of baseline periods were in multiples of 40 160 
ms, incorporating an integer number of SSVEP cycles, which prevented contamination of 161 
activity by residual SSVEP power following notch filtering. The 5 frames that comprised 162 
an epoch were baseline corrected separately to the time period -80 to 0 relative to each 163 
frame onset. Peak amplitude measurements, relative to pre-stimulus baseline activity 164 
for each component of interest were extracted.  First, the visual P1 was extracted from a 165 
cluster of occipital scalp electrode sites (O1, Oz, O2) between 95-135 ms. Second, a 166 
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frontal positive potential labeled standard-P3 was measured from a cluster of frontal 167 
scalp electrode sites (FC1, FCz, FC2) between 225-285 ms. Data for each component 168 
were analysed using a repeated measures ANOVA with factors, Drug (MPH, PLA), 169 
Accuracy (hit, miss) and Frame (standard -4, standard -3, standard -2, standard -1, target 170 
frame). The number of trials was equated for Hit and Miss conditions for each 171 
participant. The mean (min, max) number of trials for the MPH condition was 46.38 (12, 172 
99), and the Placebo condition was 50.34 (13, 92). There was no statistical difference in 173 
number of trials across the two Drug conditions, t<1.  174 
 175 
Analysis of immediate target period: Stimulus-locked data were segmented into epochs 176 
of 100 ms before to 2000 ms after target frame onset and averaged according to Drug 177 
(MPH, PLA) and accuracy (Hits, Misses). Target epochs were baseline corrected to the 178 
pre-stimulus interval and any epochs with absolute amplitude values exceeding 100mV 179 
were excluded from analysis.  The parietal P3 was confirmed by visual inspection of 180 
grand-average waveforms and scalp topographies and measured from scalp electrode 181 
site Pz. The width of the latency window used to measure component peak amplitudes 182 
was 1250ms to 1800ms relative to the onset of the target frame. The P3 onset latency 183 
was calculated as the time point at which the P3 signal reaches half of its peak voltage 184 
(23). P3 peak latency variability was calculated using the coefficient of variation (peak 185 
amplitude variability/mean amplitude).  186 
 187 
 188 
 189 
 190 
 191 
 192 
 193 
 194 
 195 
 196 
 197 
 198 
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Results 199 
 200 
Behavioural analysis 201 
 202 
There was a significant effect of drug across all conditions (n=33) on the proportion of 203 
targets detected (see Table 1), F(3,96)=14.42, p<.0001, η
2
p = .31. Pairwise comparisons 204 
showed that MPH increased the proportion of targets detected relative to placebo 205 
(p=.001), ATM (p=.0001) and CIT (p=.0001). ATM was not significantly different from PLA 206 
(p = .671). There was a marginal reduction of performance in the CIT condition 207 
compared to PLA (p = .033) but this did not survive Bonferroni correction ( p < .01). 208 
 209 
Subsequent analysis was restricted to MPH vs. PLA (n=36). MPH had no significant 210 
impact on Reaction Time (RT), t(35) = 1.54, p = .13, d = 0.26. However, we found that 211 
participants’ RT variability, as measured by the coefficient of variation, was reduced in 212 
the MPH condition compared to the PLA condition, t(35) = 3.42, p = .002, d = 0.56
1
 (see 213 
Table 2). Individual subject data are summarised in supplementary Fig. S2. 214 
 215 
A 2 × 10 ANOVA with the factors, Drug (MPH, PLA) and Block (1 to 10) was conducted to 216 
examine time-on-task effects on the target detection accuracy.  There was a Drug × 217 
Block interaction, F(9, 279) = 2.38, p = .013, η
2
p = .07, driven by a marked linear 218 
decrease in performance in the PLA condition with time (p = .0001, η
2
p = .36), which was 219 
offset by MPH (p = .84) (see supplementary Fig. S1a).  220 
 221 
 222 
 223 
 224 
 225 
                                                        
1
 N.b. The behavioural effects for target detection (p = 0.0001) and RT variability (p = 0.003) remained 
when conducted on the smallest subset of the sample (n=29) used for EEG analysis. 
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Electrophysiological Analysis
2
 226 
 227 
Long-term drug effects on the EEG amplitude spectrum 228 
 229 
We first examined EEG spectral amplitude changes induced by MPH across the entire 230 
task (n=32), averaged across all non-target frames (See Figure 2).  231 
 232 
Parietal Alpha (8-14 Hz): Participants exhibited a reduction in mean α-amplitude in the 233 
MPH compared with PLA condition, t(31) = 2.63, p = .013, d = 0.46. We also observed a 234 
decrease in mean α-amplitude variability in the MPH compared with the PLA condition, 235 
t(31) = 2.58, p = .015, d = 0.46.  236 
 237 
A subsequent Drug x Block analysis of mean α-amplitude revealed a main effect of 238 
Block, F(9, 279) = 2.19, p = .023, η
2
p = .07, indicative of a time-on-task increase in α-239 
amplitude from its lowest amplitude in block 2 to its highest in the last block (p = .01, 240 
η
2
p = .2). See supplementary Fig. S1b. There was no Drug x Block interaction, F<1.  241 
 242 
SSVEP (25Hz): SSVEP amplitudes over occipital scalp were not significantly influenced by 243 
Drug condition, t < 1, indicating that basic visual processing was not significantly 244 
enhanced by MPH. However, Bayesian analysis did not provide evidence in favour of the 245 
null hypothesis of no difference between conditions, BH(0,10) = 0.98
3
.  246 
 247 
 248 
 249 
 250 
Short-term drug effects in the pre-target interval 251 
                                                        
2 Tables of means and standard deviations are presesented for all EEG analyses in the supplementary 
materials. 
3 Criteria for calcuating Bayes Factors are described in the supplementary materials.  
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 252 
Divergences in spectral and ERP amplitude changes were analysed within a 4 s time-253 
frame before target onset as a function of Drug condition (n=29) (See Figure 3). 254 
 255 
Parietal Alpha (8-14 Hz):  A 2 × 2 ANOVA, with the factors Drug  (MPH, PLA) and 256 
Accuracy (Hit, Miss), revealed a main effect of Accuracy, F(1,28) = 6.91, p = .014, η
2
p = 257 
.20, indicating reduced α-amplitude prior to target hits compared to target misses. 258 
There was also a main effect of Drug, F(1,28) = 4.63, p=0.04, η
2
p = .14, driven by reduced 259 
α-amplitude in the pre-target period for the MPH compared with PLA condition. There 260 
was no Drug × Accuracy interaction, F < 1. 261 
 262 
SSVEP (25 Hz):  A further 2 × 2 ANOVA found no main effect of Drug, F < 1, Accuracy, F < 263 
1, or Drug × Accuracy interaction, F(1, 28) = 1.82, p = .19, η
2
p = .06 264 
 265 
P3 to standards:. P3 peak amplitude measures were entered into a 2 × 2 × 5 ANOVA 266 
with factors of Drug (MPH, PLA), Accuracy (Hit, iss) and Frame, representing  each 267 
frame in the 4 s interval up to the target frame (i.e. standard -4, standard -3, standard -268 
2, standard -1, target frame). There was a significant main effect of Accuracy, F(1,28) = 269 
49.07, p < .0001, η
2
p = .64, indicating larger P3 peak amplitudes prior to hits than 270 
misses. However, there was no main effect of Drug, F(1,28) = 2.61, p = .117, η
2
p = .09, or 271 
Frame, F(4, 112) = 2.28, p = .07, η
2
p = .08, and no significant interactions for Drug × 272 
Accuracy, F(1,28) = 2.60, p = .12, η
2
p = .08, nor Drug × Accuracy × Frame, F < 1.  There 273 
was however a significant Drug × Frame interaction, F(4, 112) = 2.59, p = .04, η
2
p = .09. 274 
Polynominal contrasts revealed a linear trend in the MPH condition with increasing P3 275 
amplitude across non-target frames until the target frame (p =  .017, η
2
p = .19), which 276 
was absent in the placebo condition (p = .62). The numerical increase in the P3 277 
amplitude across frames in the MPH condition was significantly different from the 278 
placebo condition on the target frame (p = .003, d = 0.6). 279 
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 280 
Occipital P1: A further 2 × 2 × 5 ANOVA was conducted for the peak P1 amplitude 281 
measures. There was no signficant effect of Drug, F < 1. Further, Bayesian analysis did 282 
not find evidence in support of the null hypothesis predicting no difference between 283 
conditions, BH(0,27) = 0.63.  There were no effects of Accuracy, F < 1, Frame, F(4, 112) = 284 
3.08, p = .067, η
2
p = .10, Drug x Accuracy, F(1, 28) = 2.05, p = .16, η
2
p = .07,  or Drug x 285 
Accuracy x Frame interaction, F < 1.  286 
 287 
Drug effects on target processing 288 
 289 
To examine the effects of Drug and Accuracy on immediate target processing (n=33), 290 
three features of the parietal P3 component – peak amplitude, peak latency variability 291 
and onset latency – were analysed with 2 × 2 factorial ANOVAs. Figure 5 illustrates the 292 
amplitude and onset latency effects for the parietal P3.  293 
 294 
Parietal P3 peak amplitude: We observed a main effect of Accuracy, F(1,32) = 57.35, p 295 
<.0001, η
2
p = .64, driven by greater peak amplitudes on target hits compared with 296 
misses. There was also a main effect of Drug, F(1,32) = 25.99, p <.0001, η
2
p = .45, 297 
indicating greater peak amplitudes under MPH compared with PLA, and there was no 298 
Drug × Accuracy interaction, F(1,32) = 1.92, p =.18. η
2
p = .06 299 
 300 
 Parietal P3 onset latency:  Onset latency was significantly earlier for target hits 301 
compared with misses, F(1,32) = 45.62, p <.0001, η
2
p = .59 but there was no effect of 302 
Drug  F(1,32) = 1.26, p =.27, η
2
p = .04 and no Drug × Accuracy interaction, F < 1. 303 
 304 
Parietal P3 peak latency variability:  There was a main effect of Accuracy, F(1,32) = 7.04, 305 
p = .01, η
2
p = .18, indicating that peak latency variability was reduced on target hits 306 
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compared with misses. There was no effect of Drug, F < 1, or Drug × Accuracy 307 
interaction, F < 1. 308 
  309 
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Discussion 310 
 311 
This study examined the modulation of electrophysiological precursors of lapsing 312 
attention by MPH.  Our findings demonstrate that MPH affects both the oscillatory 313 
dynamics in the α-band during sustained attention and shorter-term ERP signals in the 314 
period before and during target processing. MPH acts to avert lapses of attention and 315 
time-on-task performance decrements by reducing maladaptive neural synchronisation 316 
in the α-band over a broader time-scale, indicative of a change in attentional state or 317 
tonic alertness. Further, MPH led to a reduction in α-variability indicating that such 318 
fluctuations were less frequent.  MPH affected the frontal P3 signal, which showed a 319 
linear increase in amplitude in the pre-target period, indicative of improved task 320 
monitoring. The parietal P3 peak amplitude during the target frame was also modulated 321 
by MPH suggesting that the drug refines endogenous mechanisms that support the 322 
temporal integration of perceptual evidence required for target detection. By contrast, 323 
there was no significant effect of MPH on early sensory processing, measured by SSVEP 324 
(25 Hz) and visual P1 amplitude.   325 
 326 
These data demonstrate that attentional enhancement by MPH is supported by 327 
augmentation of electro-cortical signals across multiple times-scales, from shorter-term, 328 
phasic increases in target-related activity (P3) to longer-term tonic suppression of neural 329 
synchronisation and variability in the α-band.  In so doing, this study identifies novel 330 
markers to further understand the physiology of disorders of attention, such as ADHD, 331 
or to be leveraged as surrogate endpoints for pharmacological interventions. 332 
 333 
Greater α-band activity has previously been shown to be a strong predictor of 334 
attentional lapses during the CTET (9) and we replicate this effect here. Importantly, we 335 
also found that MPH suppressed α-amplitude and rendered oscillatory α-activity less 336 
variable across the entire task. Furthermore, α-amplitude increased with time-on-task in 337 
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both conditions but remained at a lower amplitude throughout in the MPH condition, 338 
suggesting that the threshold at which mental fatigue compromises sustained attention 339 
may be increased with MPH. Increased α-amplitude has traditionally been thought to 340 
reflect cortical idling (24) and is associated with the emergence of a resting state (25, 341 
26) in which goal-directed processes are diminished in the absence of task engagement. 342 
An alternative view, based on the α-inhibition hypothesis (27), proposes that α-343 
synchronisation reflects re-allocation of attention from an outward to an inward focus 344 
(28, 29), thus inhibition of task processing may occur during periods of task-unrelated 345 
thought that culminate in error.  346 
 347 
Simultaneous EEG-fMRI has demonstrated that α-oscillations correlate with a cingulo-348 
insular-thalamic network, which have been implicated in the maintenance of tonic 349 
alertness (30). It is noteworthy that MPH not only suppressed α-activity but also 350 
minimised the frequency of α-signal fluctuations (after controlling for differences in 351 
amplitude), facilitating the maintenance of more stable α-levels associated with 352 
improved behavioural performance. This effect is of significance given greater trial-by-353 
trial performance variability (31, 32) and neural variability (33) are prominent features in 354 
clinical disorders of attention such as ADHD. A potential mechanism by which MPH 355 
could modulate EEG alpha is through an agonistic effect on D2 receptors located in the 356 
thalamus (34) and stimulation of dopaminergic transmission via thalamocortical and 357 
mesocortical pathways. 358 
 359 
There was no significant neuromodulatory effect of MPH on early visual activity, 360 
measured by SSVEP amplitude across the entire task and neither the drug nor attention 361 
performance affected SSVEP or P1 amplitude during the pre-target 4 s period. However, 362 
Bayes Factors calculated for these non-significant effects of drug revealed no 363 
substantive evidence in support of the null hypothesis. Nevertheless, it appears 364 
reasonable to conclude that, if MPH does impact on early visual processing, its effects 365 
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are weak in comparison to the much stronger changes observed in posterior α-band 366 
activity. 367 
 368 
In addition to changes in α-activity over longer timescales, we also observed short-term 369 
changes in P3 signals. We found that a frontal P3 component was diminished in 370 
amplitude prior to misses in the pre-target interval, reproducing the same effect 371 
observed by O’Connell and colleagues (9) Furthermore, we found that MPH induced a 372 
linear increase in P3 amplitude in the pre-target period. These short-term changes 373 
suggest that MPH may help offset transient disengagement of monitoring processes 374 
that foreshadow lapses of attention.  Previous work has shown that P3 amplitude is 375 
enhanced by improved regularity of perceived rhythm (35) and enhanced attention to 376 
the regularity of the temporal pattern of the CTET may, in part, underlie the increase in 377 
P3 amplitude with MPH.  378 
 379 
MPH also increased the amplitude of the parietal P3 during target detection.  Recent 380 
research suggests that a centro-parietal positive (CPP) waveform bears a strong 381 
functional similarity to the parietal P3 and has a specific role in the formation of target 382 
decisions (36). The dynamics of this signal traces cummulative evidence of perceptual 383 
information as it evolves over time and can be clearly dissociated from signals that 384 
represent the sensory evidence (e.g., SSVEP) or motor preparation (e.g., left hemisphere 385 
beta band activity) (37). In the current study, the target frame could only be 386 
discriminated from a standard frame on the basis of a temporal judgment - in all other 387 
respects, the target and standard frames were perceptually the same. We interpret the 388 
parietal P3, as functionally equivalent to the CCP, and reflecting an endogenous process 389 
of accumulating perceptual information to support a target decision.  MPH therefore 390 
engenders greater accumulation of perceptual evidence, and we note that under MPH, 391 
even the attenuated P3 signal for missed targets was greater in amplitude than in the 392 
placebo condition and, hence, nearer a threshold level for detection. In addition to its 393 
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effect on the dopaminergic system, animal studies have reported that MPH exerts 394 
modest changes in locus coeruleus-noradrenergic (LC-NA) discharge (38). It is therefore 395 
possible that the MPH-related enhancement of the P3 may, in part, reflect 396 
noradrenergic modulation because of the strong similarities between the P3 and the 397 
phasic LC-NA responses (39, 40).  398 
 399 
In conclusion, the indirect agonistic effect of MPH on dopamine and noradrenaline 400 
affected the electrophysiological signatures of sustained attention over different time-401 
scales. We observed suppression of α-amplitude and variability supporting maintenance 402 
of tonic alertness over longer time-scales and the enhancement of P3 event-related 403 
components supporting task-related endogenous processes over shorter time-scales. At 404 
both time-scales there was an absence of change to bottom-up sensory excitability with 405 
MPH.  These findings show specificity in the electrophysiological basis by which MPH 406 
improves sustained attention and decision-making offering candidate markers for 407 
remediation of clinical disorders of attention 408 
 409 
  410 
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Table/Figure Legends 
 
Table 1.  Proportion of targets detected for the Methylphenidate (MPH), Atomoxetine 
(ATM) Citalopram (CIT) and Placebo (PLA) conditions (n=33). 
Table 2. Behavioural Results (n=36) for Methylphenidate (MPH) vs. Placebo (PLA). Mean 
(standard deviation) for the proportion of targets detected, reaction time (RT) and the 
coefficient of variation (RT standard deviation/RT mean). 
 
 
Figure 1. Task Schematic for Continuous Temporal Expectancy Task (CTET). Participants 
monitored a continuous stream of patterned stimuli centrally presented and flickering 
at a rate of 25 Hz. Standard stimuli were presented for 800 ms, and participants were 
required to monitor for the occurrence of target stimuli defined by their longer duration 
(1120 ms) relative to other stimuli. Target detection was indicated by a speeded button 
press. All participants were practiced to a criterion level of performance and completed 
10 blocks of the task. 
 
Figure 2. (A) Fast Fourier Transform (FFT) showing suppression of α band amplitude (8-
14Hz) in MPH vs. PLA condition, shown for posterior scalp site (Pz). Inset figure: α band 
amplitude variability (stdev/mean) for each subject, showing that MPH reduces alpha 
signal variability in the vast majority of subjects. (B) FFT showing parity of SSVEP (25 Hz) 
amplitude in MPH vs. PLA condition. 
 
Figure 3. (A) FFT showing greater suppression of α band amplitude (8-14 Hz) in 4 s 
period prior to a ‘hit’ vs. a ‘miss’ Greater suppression is also observed in this period for 
MPH vs. PLA (shown for parietal scalp site Pz). (B) FFT showing no changes in SSVEP (25 
Hz) amplitude in the pre-target 4 s interval as a function of accuracy or drug condition 
(shown for occipital scalp site Oz).  
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Figure 4. (A) Grand-average frontal P3 waveform for five frames in the 4 s interval 
preceding the target. The P3 was predictive of accuracy exhibiting greater peak 
amplitudes prior to a hit than a miss. There was a systematic linear increase in P3 
amplitude across frames in the MPH condition but not in the PLA condition. Differences 
between MPH and PLA were apparent on the final target frame. (B) Grand-average 
Occipital P1 waveform. No changes in the P1 component were observed in the pre-
target 4 s interval as a function of accuracy or drug condition. 
 
Figure 5 . Grand-average parietal P3 component stimulus locked to the onset of the 
target (shown for parietal scalp site Pz). In the MPH condition, compared to placebo, 
there was an increased peak P3 amplitude. There was also a greater peak amplitude on 
target hits compared to target misses. Furthermore, onset latency was earlier for target 
hits compared to misses. There was no effect of drug on onset latency of the P3. Note 
that a target frame can only be identified by participants when the frame duration 
passes that of a standard frame (800 –1120 ms). We describe this period as the target 
interval and it is marked by dashed vertical lines 
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TABLE 1 
 
 
 
 
 
 
 
 
TABLE 2 
 
 Methylphenidate  
(MPH) 
Placebo  
(PLA) 
p value & effect size 
    
Mean proportion of targets detected (n=36) 0.74 (0.21) 0.63 (0.23) 
 
p = 0.0001, d = 0.78 
Mean reaction time (RT); ms  581 (109) 602 (96) p = .13, d = 0.26 
 
Mean coefficient of variation; std/mean RT  
 
0.22 (0.04) 
 
0.24 (0.06) 
 
 
p = .002, d = 0.56 
 
 
 Methylphenidate  
(MPH) 
Atomoxetine 
(ATM) 
Citalopram   
(CIT) 
Placebo  
(PLA) 
p value & 
effect size 
      
Mean proportion of 
targets detected (n=33) 
0.75 (0.22) 0.63 (0.20) 0.60 (0.23) 0.64 (0.24) 
 
p<.0001, 
 = .31 
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